Niharika B. Mettu
Experienced in Appendix Cancer

Dr. Niharika B. Mettu

Oncology | Hematology
Duke Health
Duke Cancer Center
20 Duke Medicine Cir, 
Durham, NC 
On Staff At
Accepting New Patients
Offers Telehealth

Experienced in Appendix Cancer
Duke Health
Duke Cancer Center
20 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

My passion is the treatment of patients with gastrointestinal (GI) malignancies. I strive to take the very best care of my patients that I possibly can. Working with world-class colleagues and a multidisciplinary team, which includes radiation and surgical oncologists, makes this possible. I first became interested in oncology as a first-year medical student when I got to see tumors in my pathology class. I came to appreciate the beauty of the gastrointestinal tract while observing GI surgeries as a second-year medical student. My fascination with how cancers develop and how we may develop new therapies to treat cancer led me to pursue a PhD in molecular cancer biology. This training honed the critical thinking skills that I still use to this day, as I decide how to best treat my patients. The close relationships that oncologists have with patients and their families clinched my decision to pursue a career as a medical oncologist. During my fellowship training, I sought out subspecialty training in GI oncology. When I am not working, I enjoy spending time with my husband and four young children and running.

Dr. Mettu is rated as an Experienced provider by MediFind in the treatment of Appendix Cancer. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, and Familial Colorectal Cancer.

Her clinical research consists of co-authoring 22 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NC
Board Certifications
American Board Of Internal Med, Internal Medicine
American Board Of Internal Med, Medical Oncology
Fellowships
Hematology-Oncology, Duke University Medical Center
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
French
Hindi
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
FirstCarolinaCare
  • HMO
  • MEDICARE MAPD
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Duke Cancer Center
20 Duke Medicine Cir, Durham, NC 27710
Call: 919-681-6900

Additional Areas of Focus

Dr. Mettu has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Esophageal Cancer
Pancreatic Cancer
Colorectal Cancer
Anal Cancer
Stomach Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: August 23, 2024
Intervention Type: Other, Drug, Biological
Study Phase: Phase 2
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Enrollment Status: Terminated
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 27, 2023
Intervention Type: Drug
Study Drugs: SY-5609, Fulvestrant
Study Phase: Phase 1
A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma
A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 18, 2022
Intervention Type: Drug
Study Drugs: Eryaspase, Gemcitabine, Abraxane, Irinotecan, 5-FU, Leucovorin
Study Phase: Phase 3
A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Unknown
Publish Date: October 19, 2021
Intervention Type: Biological
Study Phase: Phase 1
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

22 Total Publications

Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 16, 2024
View All 22 Publications
Similar Doctors
Diane L. Reidy-Lagunes
Distinguished in Appendix Cancer
Dr. Diane L. Reidy-Lagunes
Hematology Oncology | Hematology | Oncology
Distinguished in Appendix Cancer
Dr. Diane L. Reidy-Lagunes
Hematology Oncology | Hematology | Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-681-6900
Languages Spoken:
English
See accepted insurances

Diane Reidy-Lagunes is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Reidy-Lagunes is rated as an Elite provider by MediFind in the treatment of Appendix Cancer. Her top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatic Cancer, Pancreaticoduodenectomy, and Liver Embolization.

Michael A. Morse
Distinguished in Appendix Cancer
Dr. Michael A. Morse
Hematology Oncology | Oncology
Distinguished in Appendix Cancer
Dr. Michael A. Morse
Hematology Oncology | Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Morse is a Hematologist Oncology specialist and an Oncologist in Durham, North Carolina. Dr. Morse is rated as a Distinguished provider by MediFind in the treatment of Appendix Cancer. His top areas of expertise are Neuroendocrine Tumor, Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Appendix Cancer, and Liver Embolization. Dr. Morse is currently accepting new patients.

John H. Strickler
Advanced in Appendix Cancer
Dr. John H. Strickler
Oncology
Advanced in Appendix Cancer
Dr. John H. Strickler
Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I specialize in the treatment of gastrointestinal (GI) cancers with a focus on clinical trials. Clinical trial patients can come to me at any point during their disease, but they usually come to me looking for an alternative therapy once standard treatments have not been effective. I decided to become a doctor later in my career. I originally graduated from university with a non-science degree, but the excitement of advancing medical breakthroughs inspired me to start a career in medicine. As a Duke physician, I enjoy the diverse experiences that I get to have each week. In addition to taking care of patients and conducting research, I work closely with other doctors on crafting treatment plans. I also find it fulfilling to be able to apply my research to patient care. In my spare time, I enjoy spending time with my family, jogging and skiing. Dr. Strickler is rated as an Elite provider by MediFind in the treatment of Appendix Cancer. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Ampullary Cancer, and Familial Colorectal Cancer.

VIEW MORE APPENDIX CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mettu's expertise for a condition
ConditionClose
    • Distinguished
    • Colorectal Cancer
      Dr. Mettu is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Mettu is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Familial Pancreatic Cancer
      Dr. Mettu is
      Distinguished
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Gastroesophageal Junction Cancer
      Dr. Mettu is
      Distinguished
      . Learn about Gastroesophageal Junction Cancer.
      See more Gastroesophageal Junction Cancer experts
    • Lynch Syndrome
      Dr. Mettu is
      Distinguished
      . Learn about Lynch Syndrome.
      See more Lynch Syndrome experts
    • Pancreatic Cancer
      Dr. Mettu is
      Distinguished
      . Learn about Pancreatic Cancer.
      See more Pancreatic Cancer experts
    • Advanced
    • Ampullary Cancer
      Dr. Mettu is
      Advanced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Cholangiocarcinoma (Bile Duct Cancer)
      Dr. Mettu is
      Advanced
      . Learn about Cholangiocarcinoma (Bile Duct Cancer).
      See more Cholangiocarcinoma (Bile Duct Cancer) experts
    • Pancreatic Ductal Adenocarcinoma
      Dr. Mettu is
      Advanced
      . Learn about Pancreatic Ductal Adenocarcinoma.
      See more Pancreatic Ductal Adenocarcinoma experts
    • Pancreatoblastoma
      Dr. Mettu is
      Advanced
      . Learn about Pancreatoblastoma.
      See more Pancreatoblastoma experts
    • Stomach Cancer
      Dr. Mettu is
      Advanced
      . Learn about Stomach Cancer.
      See more Stomach Cancer experts
    • Experienced
    • Anal Cancer
      Dr. Mettu is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Appendix Cancer
      Dr. Mettu is
      Experienced
      . Learn about Appendix Cancer.
      See more Appendix Cancer experts
    • Fibrolamellar Carcinoma
      Dr. Mettu is
      Experienced
      . Learn about Fibrolamellar Carcinoma.
      See more Fibrolamellar Carcinoma experts
    • Gallbladder Adenocarcinoma
      Dr. Mettu is
      Experienced
      . Learn about Gallbladder Adenocarcinoma.
      See more Gallbladder Adenocarcinoma experts
    • Gallbladder Cancer
      Dr. Mettu is
      Experienced
      . Learn about Gallbladder Cancer.
      See more Gallbladder Cancer experts
    • Liver Cancer
      Dr. Mettu is
      Experienced
      . Learn about Liver Cancer.
      See more Liver Cancer experts
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.